12:00 AM
Oct 08, 2012
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Subcutaneous beloranib: Phase Ib data

Data from 21 evaluable severely obese women in a double-blind, Australian Phase Ib trial showed that 1, 2 and 4 mg doses of twice-weekly subcutaneous beloranib each led to significant body weight loss from baseline to week 4 vs. placebo. Specifically, average weight loss from baseline was 4.3 kg in the low-dose beloranib arm,...

Read the full 246 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >